Pharmacyclics (PCYC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (420)	3/23/1999 10:33:00 AM
From: Biomaven	Read Replies (1) of 717

Hi Harold - The company is pretty closed mouth about their trials, which I don't have a real problem with. I expect will hear about the efficacy of the new patients in the Antrin trial in the next few months. We are probably not going to hear anything about the Gd Tex Phase III trial for a while - it's a double blind and it's just getting under way. The number of centers open for enrollment continues to climb, though. I suppose we may also hear something from the various NCI-sponsored trials that are finally getting under way. Alcon (opthalmology) has been a black hole, although according to PCYC they are conducting a Phase I trial of some sort - I suppose it must be in Europe. Their contrast-enhancer also seems to be in a black hole. Don't know if it's dead and they just don't want to make the death announcement, or they are still really doing stability studies and figuring out a new manufacturing partner. Bottom line, though, is that we get to wait for trial results. At some point there are supposed to be upwards of 15 trials running, and it is these trial results that will ultimately drive the stock. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next